References
- Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LAG, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714 - 36; http://dx.doi.org/10.1093/jnci/djr077; PMID: 21454908
- Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655 - 64; http://dx.doi.org/10.1056/NEJMra030831; PMID: 15084698
- Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458 - 68; PMID: 12359855
- Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010; 13:20 - 7; http://dx.doi.org/10.1038/pcan.2009.50; PMID: 19901958
- Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813 - 22; http://dx.doi.org/10.1016/S0140-6736(10)62344-6; PMID: 21353695
- Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 2011; 48:677 - 92; http://dx.doi.org/10.1016/j.bone.2010.11.020; PMID: 21145999
- Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of amg 162, a fully human monoclonal antibody to rankl, in postmenopausal women. J Bone Miner Res 2004; 19:1059 - 66; http://dx.doi.org/10.1359/JBMR.040305; PMID: 15176987
- Body J-J, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-05-1933; PMID: 16489077
- Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010; 28:5132 - 9; http://dx.doi.org/10.1200/JCO.2010.29.7101; PMID: 21060033
- Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125 - 32; http://dx.doi.org/10.1200/JCO.2010.31.3304; PMID: 21343556
- Matthew R, Smith FS, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab to prolong bone metastasis-free survival in men with castrate-resistant prostate cancer: Results of a global phase 3, randomized, double-blind trial. American Urological Association annual meeting. Washington, D.C. 2011.
- Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009; 115:1631 - 7; http://dx.doi.org/10.1002/cncr.24119; PMID: 19156913
- Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and Time to Osteonecrosis Development. Oncologist 2009; 14:1154 - 66; http://dx.doi.org/10.1634/theoncologist.2009-0115; PMID: 19897878